Carlisle (CSL - Free Report) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CSL broke out above the 50-day moving average, suggesting a short-term bullish trend.
One of the three major moving averages, the 50-day simple moving average is commonly used by traders and analysts to determine support or resistance levels for different types of securities. However, the 50-day is considered to be more important since it's the first marker of an up or down trend.
CSL could be on the verge of another rally after moving 7.3% higher over the last four weeks. Plus, the company is currently a Zacks Rank #3 (Hold) stock.
The bullish case solidifies once investors consider CSL's positive earnings estimate revisions. No estimate has gone lower in the past two months for the current fiscal year, compared to 2 higher, while the consensus estimate has increased too.
Investors should think about putting CSL on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions.
After reaching an important support level, Carlisle (CSL) could be a good stock pick from a technical perspective. CSL surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Companies that have raised dividends for shareholders for 50 years or more are the kinds of investments passive income investors need to own. Dependability is crucial for individuals seeking to increase their annual income through dividend stock investments. The Dividend Kings are the 57 companies that have raised their dividends for at least 50 years, a testament to their dependability and reliability. Those are two “must-have” qualities for investors who rely on passive income to boost their overall income. Unlike the Dividend Aristocrats, Dividend Kings do not have to be members of the S&P 500.
We decided to screen our 24/7 Wall St. dividend stocks database, looking for companies likely to be enshrined as Dividend Kings based on past dividend payments and increases over the years. Four top companies that most investors are familiar with are poised to join this list this year, and all look like outstanding buys for growth and income investors looking for dependable dividend streams and solid growth potential. All four are covered by the top Wall Street firms we track.
Why we recommend the Dividend Kings Companies that have paid and raised dividends for 50 years or more are the kinds of stocks growth and income investors want to buy and hold in stock portfolios forever. These stocks are mostly conservative, and should a dramatic market correction occur, they will likely hold their ground much better than volatile technology names.
Carlisle Companies Industrials and construction materials giant Carlisle Companies (NYSE: CSL | CSL Price Prediction) is an industrial name nearing the threshold, with analysts flagging it as a strong candidate for inclusion in 2026. The company is a manufacturer and supplier of building envelope products and solutions that enable energy efficiency in buildings, and it pays a 1.24% dividend.
Its segments include Carlisle Construction Materials (CCM) and Carlisle Weatherproofing Technologies (CWT). The former produces a complete line of energy-efficient single-ply roofing products, warranted roof systems, and accessories for the commercial building industry, including:
Ethylene propylene diene monomer Thermoplastic polyolefin and polyvinyl chloride membrane Polyisocyanurate insulation Engineered metal roofing and wall panel systems for commercial and residential buildings The CWT segment produces building envelope solutions that drive energy efficiency and sustainability in commercial and residential applications. Its products include waterproofing and moisture protection products, protective roofing underlayments, fully integrated liquid- and sheet-applied air/vapor barriers, and others.
Raymond James has an Outperform rating with a $425 target price.
Clorox With products that never go out of style, a 26% discount, a 0.74 price-to-fair-value ratio, and a massive 5.39% dividend, Clorox (NYSE: CLX) is the perfect buy for conservative investors. The company is a multinational manufacturer and marketer of consumer and professional products. Despite some earnings turbulence in recent years, Clorox has maintained its dividend streak and is expected to cross the 50-year mark in 2026.
The company operates through four segments:
Health and Wellness Household Lifestyle International The Health and Wellness segment consists of cleaning, disinfecting, and professional products marketed and sold under these brands:
Clorox Clorox2 Pine-Sol Scentiva Tilex Liquid-Plumr Formula 409 Its Household segment consists of bags and wraps, cat litter, and grilling products marketed and sold under the Glad, Fresh Step, Scoop Away, and Kingsford brands in the United States. The Lifestyle segment consists of food, water-filtration, and natural personal care products marketed and sold under the Hidden Valley, Brita, and Burt’s Bees brands.
International products consist of those sold outside the United States. Its products in this segment include laundry additives, home care products, bags and wraps, cat litter, water filtration products, and others.
Jefferies has a Buy rating with a $139 price target.
McDonald’s This American multinational fast-food chain is a solid pick when the economy goes south or north. McDonald’s (NYSE: MCD) is among the safest large-cap restaurant ideas, and it pays a solid 2.63% dividend. The payout is approaching the 50-year mark, and the company is widely seen as a likely entrant, given its consistent dividend growth and durable business model.
McDonald’s operates and franchises its restaurants globally. Approximately 95% of McDonald’s roughly 13,500 U.S. restaurants are owned and operated by independent franchisees. The restaurants offer:
Hamburgers and cheeseburgers Chicken sandwiches and nuggets Fries Salads Shakes Frozen desserts Sundaes Soft serve cones Bakery items Soft drinks Coffee Muffins Sausages Biscuit and bagel sandwiches Oatmeal Hash browns Breakfast burritos Hotcakes BTIG has a Buy rating with a $370 target price for the shares.
Sysco Not to be confused with the tech giant, this food distributor pays a solid 2.96% dividend and is an ideal blue chip for conservative investors. Sysco (NYSE: SYY) is a global distributor of food and related products primarily to the foodservice or food-away-from-home industry. This company has 49 years of consecutive annual dividend increases and would be eligible for inclusion among the Dividend Kings in 2026. It is one of the most-watched candidates this year.
Sysco distributes a variety of products, including frozen, canned, and dry foods, fresh meats and seafood, and more. Its U.S. Foodservice Operations segment primarily includes its U.S. broad-line operations, which distribute a line of food products, including custom-cut meat, seafood, produce, specialty Italian, specialty imports, and a variety of non-food products.
The International Foodservice Operations segment includes operations outside the United States that distribute a line of food products and a variety of non-food products. Meanwhile, the SYGMA segment is engaged in customized distribution operations serving quick-service chain restaurant customer locations, and the Other segment primarily includes its hotel supply operations, Guest Worldwide.
On May 15, 2026, Carlisle Companies Inc CSL shares fell 4.9%, closing at $332.49. The stock has experienced a 52-week high of $435.92 and a low of $293.43, reflecting a challenging year for the company.
GF Value™ verdict: Current price is $332.49, which is 17.4% below the GF Value™ of $402.59.GF Score™ is 93/100, indicating a strong overall performance.Most notable signal: Insiders sold $0.1M worth of stock in the last three months, with no buying activity. Is CSL Overvalued or Undervalued? Carlisle Companies Inc CSL is currently trading at $332.49, which is significantly below its GF Value™ estimate of $402.59. This presents a margin of safety of 17.4%, suggesting that the stock may be undervalued at its current price. The GF Valuation label categorizes CSL as "Modestly Undervalued," indicating that there may be an opportunity for potential upside. However, investors should remain cautious given the recent insider selling trends, as this could be interpreted as a lack of confidence in the stock's near-term performance.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. The valuation suggests that while there is potential for growth, external market conditions and insider activity could pose risks that investors need to consider.
How Does CSL's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 19.6x 19.3x Forward P/E 16.1x N/A The current P/E ratio of 19.6x is slightly above the 5-year median P/E of 19.3x, indicating that the stock is trading at a premium compared to its historical valuation. When comparing the current P/E to the forward P/E of 16.1x, it suggests that the market may be expecting future earnings growth, which aligns with the GF Value™ verdict that indicates CSL is undervalued. This P/E analysis corroborates the GF Value™ assessment, highlighting the potential for value in the stock based on future earnings expectations.
What Does CSL's GF Score™ Tell Us? Metric Rating GF Score™ 93 Financial Strength 6/10 Profitability 9/10 Growth 9/10 Valuation 10/10 Momentum 7/10 The GF Score™ of 93/100 highlights Carlisle Companies Inc as a strong investment candidate based on various metrics. The highest scores are in Profitability (9/10), Growth (9/10), and Valuation (10/10), indicating robust financial performance and healthy market positioning. However, the Financial Strength score of 6/10 suggests some areas of improvement are needed, which could raise concerns regarding the company's resilience in challenging economic conditions. Overall, the strong GF Score™ supports the undervalued status of CSL, but investors should consider its financial metrics alongside the market conditions.
What Are Insiders Doing with CSL Stock? Recent insider activity shows that insiders sold $0.1M worth of stocks in the last three months, with no buying activity reported. This pattern may suggest a lack of confidence from insiders regarding the stock's near-term prospects. While insider selling can sometimes indicate a lack of faith in the company's future performance, it can also occur for personal financial reasons unrelated to the company's fundamentals. Therefore, potential investors may want to consider this alongside other performance metrics before making any decisions.
What This Means for Investors Based on the GF Value™ assessment, Carlisle Companies Inc CSL is currently undervalued. With a current price of $332.49 compared to a GF Value™ of $402.59, there is a significant opportunity for potential price appreciation. However, the recent insider selling and moderate financial strength score suggest that caution is warranted.
For the complete analysis, visit the Carlisle Companies Inc CSL stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is CSL's GF Score™?
CSL's GF Score™ is 93/100, indicating a strong overall performance based on key financial metrics. Higher GF Score™ values have been associated with higher long-term returns.
Is CSL overvalued or undervalued?
CSL is currently undervalued according to the GF Value™, with a current price of $332.49 being 17.4% below its estimated fair value of $402.59.
What is CSL's P/E ratio?
CSL's P/E ratio (TTM) is 19.6x, which is slightly above its 5-year median of 19.3x, indicating that it is trading at a premium compared to its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
The first list of 8 companies that could reach Dividend King status in coming years. These companies provide investors a wide range of starting dividend yields and growth histories. It's possible one or more of these companies do not attain Dividend King status.
CompaniesMay 27 (Reuters) - The vaccine arm of Australian biopharmaceutical giant CSL (CSL.AX), opens new tab said on Wednesday it will discontinue sales of an injectable medicine used to treat bacterial infections, citing the availability of several generic alternatives.
CSL's Seqirus notified the country's medicine regulator, Therapeutic Goods Administration (TGA), that it will progressively discontinue all strengths of Benpen injection products, beginning with the 600 milligram (mg) dose from the end of November.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
"CSL Seqirus will no longer supply Benpen to the Australian market, due to the registration of several generic products," the vaccine unit said.
Benzylpenicillin sodium, opens new tab, the active ingredient in Benpen, is an injectable antibiotic widely used to treat bacterial infections following surgery and other medical procedures.
"The discontinuations are due to commercial decisions and are not related to product safety, quality or effectiveness," the TGA said, adding that the supply of the injection will continue until the existing stock is exhausted.
Alternative Australian-registered benzylpenicillin sodium injection brands are expected to be available in the future, the regulator said.
Reporting by Shivangi Lahiri in Bengaluru, Additional reporting by Shruti Agarwal; Editing by Nivedita Bhattacharjee and Eileen Soreng
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Key Takeaways AVT posted Q3 revenues of $7.1B, up 34% Y/Y, driven by data center, networking and industrial demand.Avnet's AI and data center exposure rose to 10-15%, led by hyperscaler demand in Taiwan.AVT expects Q4 revenues of $7.3-$7.6B as backlog growth and tight supply support growth momentum. Avnet Inc. (AVT - Free Report) is benefiting from strong demand in AI infrastructure, networking and industrial markets. In the third quarter of fiscal 2026, the company reported revenues of $7.1 billion, up 34% year over year and 13% sequentially. Management stated that AI data center, networking and industrial markets were the biggest growth drivers during the third quarter. The company also delivered record sales of $6.67 billion in its Electronic Components business, which increased 34.7% year over year on the back of robust demand across most end markets.
AI-related demand is becoming a larger part of AVT’s business. In the third quarter of fiscal 2026, management stated that the company’s direct exposure to AI and data center customers has increased from around 5-7% previously to nearly 10-15% now. Most of this business is tied to Asia, especially Taiwan, where demand from hyperscalers and server customers remains strong. Networking demand also improved across regions, with the Americas showing strong growth during the third quarter.
The company is also benefiting from demand for components that support AI infrastructure. AI buildouts are increasing demand for products tied to power management, cooling systems, connectors, capacitors, resistors and sensors. This helped AVT’s interconnect, passive and electromechanical (IP&E) business grow 25% year over year in the third quarter. The company noted that every AI accelerator requires surrounding IP&E products, creating additional sales opportunities beyond semiconductors.
AVT expects current demand trends to continue in the near term. With growing backlog levels and book-to-bill ratios above parity across all regions, supported by rising lead times across several component categories as supply conditions tighten, AVT remains well-positioned to continue seeing strong business momentum in the near term. For the fourth quarter of fiscal 2026, AVT expects revenues to be in the range of $7.3-$7.6 billion, implying approximately 5% sequential growth at the midpoint. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $7.46 billion, implying year-over-year growth of 32.8%.
How Competitors Fare Against AvnetAvnet faces stiff competition from other global technology solutions providers such as Arrow Electronics Inc. (ARW - Free Report) and TD SYNNEX (SNX - Free Report) .
Arrow Electronics is one of the world’s largest distributors of electronic components, which focuses on selling semiconductor products, IP&E components and IT hardware and software to original equipment manufacturers and electronics manufacturing services providers. Arrow Electronics is witnessing robust growth in its Global Components segment, through which the company deals in semiconductor products and related services. In the first quarter of 2026, Global Component sales increased 39% year over year on a reported basis and 35% on a constant currency basis to $6.64 billion.
TD SYNNEX is a leading global IT distributor and solutions aggregator, providing a comprehensive range of technology distribution, logistics and integration services. TD SYNNEX’s portfolio includes cloud computing, cybersecurity, AI, networking, data center infrastructure and consumer electronics. In the first quarter of fiscal 2026, TD SYNNEX’s Hyve division, which focuses on hyperscale infrastructure solutions, noted strong growth in gross billings, driven by surging demand for cloud data centers and AI-powered workloads.
AVT’s Price Performance, Valuation & EstimatesShares of AVT have surged 72.3% in the year-to-date period compared with the Zacks Electronics - Parts Distribution industry’s appreciation of 58%.
AVT YTD Price Return Performance
Image Source: Zacks Investment Research
In terms of forward price/sales, Avnet is trading at 0.25X compared with the industry’s 0.4X.
The Zacks Consensus Estimate for Avnet’s fiscal 2026 earnings is pegged at $4.92 per share, revised up by 30 cents over the past 30 days, marking a year-over-year increase of 43%.
Image Source: Zacks Investment Research
Avent currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Avnet (AVT - Free Report) , a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Avnet currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for AVT that show why this distributor of electronic components shows promise as a solid momentum pick.
Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For AVT, shares are up 2.2% over the past week while the Zacks Electronics - Parts Distribution industry is up 3.48% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 9.3% compares favorably with the industry's 15.21% performance as well.
While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Over the past quarter, shares of Avnet have risen 32.21%, and are up 72.79% in the last year. In comparison, the S&P 500 has only moved 7.85% and 30.1%, respectively.
Investors should also take note of AVT's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now AVT is averaging 1,366,360 shares for the last 20 days..
Earnings OutlookThe Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with AVT.
Over the past two months, 3 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost AVT's consensus estimate, increasing from $4.62 to $5.12 in the past 60 days. Looking at the next fiscal year, 3 estimates have moved upwards while there have been no downward revisions in the same time period.
Bottom LineTaking into account all of these elements, it should come as no surprise that AVT is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Avnet on your short list.
Key Takeaways Earnings yield is calculated by dividing a company's EPS by its current stock price.A higher earnings yield indicates that a stock may be undervalued and could provide growth potential.LYB, NEXA, CVX, AVT and SHIP are a few solid high earnings yield value stocks. Tensions between the United States and Iran continue as both sides exchange military strikes. Iran’s Revolutionary Guard attacked a U.S. air base after American forces reportedly targeted Iranian drones and launch sites near the Strait of Hormuz. There is no clear sign of peace talks succeeding yet. U.S. President Trump said he is in no hurry to strike a deal and insisted Iran cannot simply wait for U.S. election pressure to weaken his stance. The White House also dismissed reports that the United States may ease restrictions on Iran in exchange for reopening the vital oil shipping route, signaling that both military and political tensions remain high.
Uncertainty around when a deal might be reached has kept central banks cautious, as policymakers assess whether higher energy prices could fuel inflation and require tighter monetary policy. In such an environment, value investing appears particularly prudent, as investors tend to favor fundamentally strong, reasonably valued companies that can better withstand economic and market volatility. This approach hinges on the idea that market prices often don’t fully reflect a company’s fundamentals, providing opportunities to benefit from market corrections in the long run.
LyondellBasell Industries (LYB - Free Report) , Nexa Resources S.A. (NEXA - Free Report) , Chevron Corp. (CVX - Free Report) , Seanergy Maritime Holdings Corp. (SHIP - Free Report) and Avnet, Inc. (AVT - Free Report) are a few solid high earnings yield picks for value investors.
Unlock Portfolio Value With Earnings YieldEarnings yield is calculated by dividing a company’s earnings per share (EPS) by its current stock price (Earnings Yield = EPS / Current Stock Price). This figure represents the profit generated for each dollar invested, effectively serving as the inverse of the price-to-earnings (P/E) ratio. A higher earnings yield typically indicates that a stock may be undervalued and could provide growth potential, while a lower earnings yield could suggest overvaluation.
Beyond identifying individual stocks, earnings yield also aids in comparing the stock market to fixed-income investments, like 10-year Treasury bonds. If the earnings yield of a market index surpasses the bond yield, it can indicate favorable conditions for investing in stocks over bonds, which is valuable for portfolio diversification.
The Winning StrategyWe have set an Earnings Yield greater than 10% as our primary screening criterion but it alone cannot be used for picking stocks that have the potential to generate solid returns. So, we have added the following parameters to the screen:
Estimated EPS growth for the next 12 months greater than or equal to the S&P 500: This metric compares the 12-month forward EPS estimate with the 12-month actual EPS.
Average Daily Volume (20 Day) greater than or equal to 100,000: High trading volume implies that a stock has adequate liquidity.
Current Price greater than or equal to $5.
Buy-Rated Stocks: Stocks with a Zacks Rank #1 (Strong Buy) or 2 (Buy) have been known to outperform peers in any type of market environment. You can see the complete list of today’s Zacks #1 Rank stocks here.
Our PicksHere we discuss five of the 38 stocks that qualified the screening:
LyondellBasell is among the world’s leading plastics, chemicals, and refining companies, serving a wide range of industries including electronics, automotive parts, packaging, construction materials, and biofuels.The Zacks Consensus Estimate for LYB’s 2026 sales and earnings implies year-over-year growth of 12% and 414%, respectively. EPS estimates for the current and next year have moved up by $3.29 and $2.19, respectively, over the past 30 days. LyondellBasell currently sports a Zacks Rank #1 and has a Value Score of B.
Nexa Resources is an integrated zinc producer, engaged in developing and operating mining and smelting assets, primarily in Latin America. The Zacks Consensus Estimate for NEXA’s 2026 sales and earnings implies year-over-year growth of 15% and 214%, respectively. EPS estimates for the current and next year have moved up by 87 cents and 37 cents, respectively, over the past 30 days. Nexa Resources currently carries a Zacks Rank #1 and has a Value Score of A.
Chevron is one of the world’s largest integrated energy companies, with operations spanning oil production, refining, and marketing across global markets. The Zacks Consensus Estimate for CVX’s 2026 sales and earnings implies year-over-year growth of 16% and 116%, respectively. EPS estimates for the current and next year have moved up by $2.19 and 80 cents, respectively, over the past 30 days. Chevron currently sports a Zacks Rank #1 and has a Value Score of B.
Seanergy Maritime is a global shipping firm focused on transporting dry bulk commodities by sea. The Zacks Consensus Estimate for SHIP’s 2026 sales and earnings implies year-over-year growth of 16% and 63%, respectively. EPS estimates for the current and next year have moved up by 13 cents and 10 cents, respectively, over the past 60 days. Seanergy Maritime currently sports a Zacks Rank #1 and has a Value Score of B.
Avnet is a leading global distributor of electronic components and computer products, serving OEMs, manufacturing services providers, design manufacturers, and value-added resellers. The Zacks Consensus Estimate for AVT’s fiscal 2026 sales and earnings implies year-over-year growth of 21% and 49%, respectively. EPS estimates for the current and next fiscal have moved up by 50 cents and 86 cents, respectively, over the past 30 days. Avnet currently carries a Zacks Rank #2 and has a Value Score of A.
It has been about a month since the last earnings report for Avnet (AVT - Free Report) . Shares have added about 5.6% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Avnet due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.
Avnet's Q3 Earnings Beat Estimates on Record Components SalesAvnet reported better-than-expected third-quarter fiscal 2026 results. The company’s third-quarter adjusted earnings of $1.48 per share beat the Zacks Consensus Estimate by 11.28%. The bottom line surged 76.2% on a year-over-year basis.
Net sales increased 34% year over year to $7.12 billion and surpassed the consensus mark by 12.09%. The robust third-quarter performance was mainly driven by strength across served markets and record performance in the Electronic Components segment.
Avnet’s Segment Results Show Strength in Core DistributionIn the Electronic Components segment, sales increased 34.7% year over year to $6.67 billion, while operating income margin expanded 5 basis points (bps) to 3.5%. The quarter included record sales for Electronic Components, aided by growth across regions and demand creation activity.
Farnell revenues increased 24% year over year to $454.7 million, and operating income margin expanded 224 bps to 5.2%, marking continued progress in business recovery. Management stated that the ongoing investments in the e-commerce platform and customer experience will help improve the segment’s profitability.
Avnet Sees Broad-Based Demand Lift Across RegionsAVT’s year-over-year revenue growth reflected strength across geographies, led by Asia, where sales increased 39.3% to $3.46 billion and represented 49% of total company sales during the quarter. EMEA revenues climbed 31.3% to $2.05 billion, while the Americas posted a 26.7% increase to $1.62 billion.
Management linked the quarter’s momentum to improving market conditions across core end markets, including industrial, networking and data center, with demand improving across most verticals served. The company also noted lead times trending higher across many component categories, a backdrop that can influence customer ordering patterns.
Avnet’s Margins Improve Sequentially Despite Mix PressureAvnet reported a gross margin of 10.4% in the quarter, down 68 basis points year over year, which management attributed largely to sales mix, including a higher percentage of revenues coming from Asia and mix differences in Western regions.
Even with that pressure, profitability improved sequentially. Operating income margin expanded 19 bps to 2.9%, and adjusted operating income margin improved 23 bps to 3.1%, reflecting better operating leverage as volumes recovered, particularly in the West.
AVT Benefits From Pricing Tailwind Concentrated in MemoryA notable development in the quarter was the impact of higher component pricing, most prominently in memory. Management indicated that pricing increases contributed meaningfully to the sales trajectory, with roughly half of sequential sales growth and about one quarter of year-over-year sales growth tied to higher memory pricing.
Avnet emphasized that price increases generally pass through to customers, which can lift gross profit dollars without materially boosting gross margin percentage. It also flagged the potential for additional, smaller price increases across other technologies in the coming months.
Balance Sheet & Cash Flow of AvnetAs of March 28, 2026, AVT had cash and cash equivalents of $202.4 million compared with $286.5 million reported as of Dec. 27, 2025.
The long-term debt was $2.47 billion as of March 28, 2026, unchanged from the previous quarter. Gross debt leverage was 3.6X at the end of the third quarter, and management reiterated its goal to reduce leverage to roughly 3X by the end of 2026.
In the first three quarters of fiscal 2026, Avnet generated operating cash flow of $9.8 million. During the same period, it repurchased shares worth $138.3 million and paid $85.6 million in dividends.
Avnet’s Outlook Calls for Continued Sequential GrowthFor the fourth quarter of fiscal 2026, Avnet projects revenues in the range of $7.30-$7.60 billion, which implies approximately 5% sequential growth at the midpoint. The company anticipates adjusted earnings between $1.70 and $1.80 per share, assuming similar interest expense to the third quarter and an adjusted effective tax rate between 21% and 25%. The Zacks Consensus Estimate for fourth-quarter revenues and earnings is pegged at $6.11 billion and $1.46 per share, respectively.
Operationally, management described book-to-bill ratios as well above parity in all regions and noted backlog growth as customers respond to a tightening supply environment. The company said that its guidance assumes current market conditions persist, with Electronic Components sales growth expected across all regions.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates review.
The consensus estimate has shifted 20.73% due to these changes.
VGM ScoresAt this time, Avnet has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. However, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Avnet has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
On June 02, 2026, Avnet Inc AVT shares rose 6.8% to a current price of $92.93, marking a significant increase over the past month with a rise of 15.4%. Over the last year, AVT has experienced a remarkable year-to-date increase of 94.3%, peaking at $95.26 and reaching a low of $44.25 in the past 52 weeks.
GF Value™ verdict: Current price is $92.93, compared to GF Value™ of $61.85, indicating the stock is 50.3% overvalued.GF Score™: 86/100 (Strong), suggesting a solid performance across multiple metrics.Notable signal: Insiders sold $3.0M in the last 3 months, indicating a lack of buying interest. Is AVT Overvalued or Undervalued? Avnet Inc's current price of $92.93 significantly exceeds the GF Value™ estimate of $61.85, resulting in a 50.3% overvaluation. This discrepancy indicates a lack of margin of safety for potential investors, as the current valuation does not reflect the intrinsic value derived from the company's historical performance and growth prospects. The GF Valuation label identifies AVT as "Significantly Overvalued," which raises concerns about the sustainability of the current price level. Potential risks associated with investing in overvalued stocks include increased volatility and the possibility of price corrections in the future.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
How Does AVT's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 36.2x 9.4x (5-Year Median) Forward P/E 11.8x - Avnet's current P/E (TTM) of 36.2x is drastically above its 5-year median P/E of 9.4x, indicating that the stock is trading at a significantly higher valuation compared to its historical average. The forward P/E of 11.8x still suggests a premium compared to historical standards. This analysis aligns with the GF Value™ verdict, confirming that AVT is overvalued relative to its historical valuation metrics.
What Does AVT's GF Score™ Tell Us? Metric Rating GF Score™ 86 Financial Strength 6/10 Profitability 7/10 Growth 9/10 Valuation 5/10 Momentum 9/10 The GF Score™ of 86/100 indicates a strong overall rating, reflecting solid performance in various areas. The strongest aspect is Growth (9/10), suggesting that the company has robust growth prospects. However, the Valuation rank of 5/10 indicates that the stock's current valuation may not be favorable. Financial Strength (6/10) and Profitability (7/10) scores further emphasize that while AVT is performing well, there are areas of concern that investors should consider.
What Are Insiders Doing with AVT Stock? In the last three months, insiders have sold $3.0M worth of Avnet stock, with no purchases reported. This pattern of selling rather than buying may signal a lack of confidence among insiders regarding the company's future performance or valuation levels. Insider selling can often indicate that those closest to the company believe the stock is overvalued or that they are seeking to liquidate for personal financial reasons.
What This Means for Investors Based on the current analysis and the GF Value™ estimate, Avnet Inc AVT is considered overvalued. The significant discrepancy between the current share price and the GF Value™ suggests that potential investors may want to exercise caution or seek additional confirmation before proceeding.
For the complete analysis, visit the Avnet Inc AVT stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is AVT's GF Score™?
AVT's GF Score™ is 86/100, indicating a strong performance across key metrics that usually correlate with higher long-term returns.
Is AVT overvalued or undervalued?
AVT is considered overvalued, with a current price significantly exceeding the GF Value™ estimate, suggesting potential risks for investors.
What is AVT's P/E ratio?
AVT's current P/E (TTM) is 36.2x, which is considerably higher than its 5-year median P/E of 9.4x, indicating a substantial premium in its valuation compared to historical levels.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Key Takeaways Low P/CF screen flags NEXA, AVT, STNE and USNA as value stocks amid market uncertainty.NEXA and AVT have sales/EPS growth forecasts, and shares rose 144.6% and 65.7% in a year.STNE and USNA also have sales/EPS growth forecasts, but shares fell 24% and 35.7% in a year. Value investing is considered one of the best practices when it comes to picking stocks at a time when the market is juggling with geopolitical tensions. It is essentially about selecting stocks that are fundamentally sound but have been beaten down by some external factors. Such stocks are poised to bounce back as and when investors recognize the inherent value of companies. The value investment strategy best suits investors with a long-term horizon.
Often trading below their intrinsic value, these stocks provide a margin of safety that is especially appealing during periods of market uncertainty. When evaluating value stocks, one of the most effective valuation metrics is the Price-to-Cash-Flow (P/CF) ratio.
Companies, such as Nexa Resources S.A. (NEXA - Free Report) , Avnet, Inc. (AVT - Free Report) , StoneCo Ltd. (STNE - Free Report) and USANA Health Sciences, Inc. (USNA - Free Report) , boast a low P/CF ratio. The P/CF ratio evaluates the market price of a stock relative to the amount of cash flow that the company is generating on a per-share basis — the lower the number, the better.
Price-to-Cash-Flow metric evaluates the market price of a stock relative to the amount of cash flow that the company is generating on a per-share basis — the lower the number, the better. One of the important factors that makes P/CF a highly dependable metric is that operating cash flow adds back non-cash charges such as depreciation and amortization to net income, truly diagnosing a company's financial health.
Analysts caution that a company’s earnings are subject to accounting estimates and management manipulation. However, cash flow is reliable. Net cash flow unveils how much money a company is actually generating and how effectively management is deploying the same.
Positive cash flow indicates an increase in a company’s liquid assets. It gives the company the means to settle debt, meet its expenses, reinvest in its business, endure downturns and finally pay back its shareholders. Negative cash flow implies a decline in the company’s liquidity, which in turn lowers its flexibility to support these moves.
What’s the Best Value Investing Strategy?An investment decision based solely on the P/CF metric may not yield the desired results. To identify stocks that are trading at a discount, you should expand your search criteria and also consider the price-to-book ratio, price-to-earnings ratio, and price-to-sales ratio. Adding a favorable Zacks Rank and a Value Score of A or B to your search criteria should lead to even better results as these eliminate the chance of falling into a value trap.
Here are the parameters for selecting true-value stocks:
P/CF less than or equal to X-Industry Median.
Price greater than or equal to 5: The stocks must all be trading at a minimum of $5 or higher.
Average 20-Day Volume greater than 100,000: A substantial trading volume ensures that the stock is easily tradable.
P/E using (F1) less than or equal to X-Industry Median: This parameter shortlists stocks that are trading at a discount or are equal to their peers.
P/B less than or equal to X-Industry Median: A lower P/B compared with the industry average implies that there is enough room for the stock to gain.
P/S less than or equal to X-Industry Median: The P/S ratio determines how a stock price compares to the company’s sales — the lower the ratio, the more attractive the stock is.
PEG less than 1: The ratio is used to determine a stock's value by taking the company's earnings growth into account. The PEG ratio gives a more complete picture than the P/E ratio. A value of less than 1 indicates that the stock is undervalued and that investors need to pay less for a stock that has robust earnings growth prospects.
Zacks Rank less than or equal to 2: Zacks Rank #1 (Strong Buy) or 2 (Buy) stocks are known to outperform irrespective of the market environment.
Value Score of less than or equal to B: Our research shows that stocks with a Style Score of A or B, when combined with Zacks Rank #1 or 2, offer the best upside potential.
Here are four of the 11 value stocks that qualified the screening:
Nexa Resources, a large-scale, low-cost, integrated polymetallic producer, sports a Zacks Rank #1. The company has a trailing four-quarter earnings surprise of 59.9%, on average. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Nexa Resources’ current financial-year sales and EPS implies growth of 14.6% and 214.1%, respectively, from the year-ago period. NEXA has a Value Score of A. Shares of NEXA have soared 144.6% over the past year.
Avnet, a leading global technology distributor and solutions provider, carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 9.5%, on average.
The Zacks Consensus Estimate for Avnet’s current financial-year sales and EPS indicates growth of 20.7% and 48.8%, respectively, from the year-ago period. AVT has a Value Score of B. Shares of AVT have surged 65.7% over the past year.
Stone, a leading provider of financial technology solutions, carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 3.1%, on average.
The Zacks Consensus Estimate for Stone’s current financial-year sales and EPS indicates growth of 10.3% and 42.6%, respectively, from the year-ago period. STNE has a Value Score of A. Shares of STNE have fallen 24% over the past year.
USANA Health, which develops and manufactures high-quality nutritional supplements, functional foods and personal care products, carries a Zacks Rank #2. The company has a trailing four-quarter earnings surprise of 30.5%, on average.
The Zacks Consensus Estimate for USANA Health’s current financial-year sales and EPS calls for growth of 2.1% and 9.8%, respectively, from the year-ago period. USNA has a Value Score of A. Shares of USNA have declined 35.7% over the past year.
GSK PLC (LSE:GSK, NYSE:GSK) shares fell 3% after it agreed to acquire US biotechnology company Nuvalent (NASDAQ:NUVL) for $10.6 billion (£8.0 billion), adding immediate new revenues and a trio of lung cancer drugs in advanced development.
The FTSE 100 pharmaceuticals group said the deal would contribute to revenue growth from 2027 and be accretive to core operating profit in 2027 and core earnings per share in 2029, including synergies and reprioritisation.
The company maintained its 2026 guidance and said it remained committed to its expected 70p dividend for the year.
GSK will pay $124 a share in cash for Nuvalent, representing a 40% premium to the Boston-based outfit's last closing price. Net of cash acquired, GSK's investment is expected to be about $9.4 billion (£7.1 billion).
The transaction will be funded through a mix of cash and debt.
Luke Miels, chief executive of GSK, said: "Today's acquisition is a multi-product deal, consistent with our approach to acquire assets that have clinically proven targets and meaningfully address an efficacy and/or tolerability gap."
He added: "The acquisition provides GSK with immediate new sales growth opportunities, improving profit contributions from 2027, and a platform in lung cancer for rapid expansion with Ris-Rez, our B7-H3 targeted ADC in phase III clinical development."
GSK highlighted the additions of zidesamtinib and neladalkib, two late-stage treatments for non-small cell lung cancer that are currently under review by the US Food & Drug Administration, with target decision dates in September and November.
Both drugs have received FDA Breakthrough Therapy and Orphan Drug designations and, subject to approval, are expected to launch this year. GSK said the medicines have multi-blockbuster potential.
The acquisition also includes NVL-330, a HER2 inhibitor in phase I trials, together with Nuvalent's wider preclinical portfolio.
GSK shares fell 3.5% to 1,845p in Tuesday morning trading.
Following speculative reports of a deal overnight, UBS analyst Matthew Weston said he would view a Nuvalent acquisition "as broadly in line with GSK's oncology strategy of targeting smaller subsets of patients with differentiated products but where the mode of action is already validated.
"We would expect investors may be surprised at the size of a potential acquisition >$9bn given management's previous commentary that $2-4 billion is their preferred deal size."
Offsetting this deal size, he said, is the fact that Nuvalent has two late-stage assets with validated pivotal data "which have the potential to contribute to sales and earnings trajectory pre-2030".
UBS's US biotech analysts forecast peak sales expectations for lead asset zidesamtinib in ROS-1 mutant lung cancer of $1.7 billion, versus the wider Wall Street consensus at $700 million.
** UPDATE: Adds share price and analyst comments **
GlaxoSmithKline is making its largest oncology acquisition in years with a $10.6 billion deal for US-based cancer drug developer Nuvalent, betting that a trio of promising lung cancer therapies can help drive future growth and offset looming patent expirations in its HIV portfolio.
The acquisition, announced on Tuesday, will give the British pharmaceutical giant access to three experimental lung cancer treatments, including two candidates currently under review by the US Food and Drug Administration and expected to receive regulatory decisions later this year.
While the deal strengthens GSK’s long-term ambitions in oncology, investors appeared unconvinced by the scale and price of the transaction.
GSK shares fell around 3% in early trading, making the stock one of the weakest performers on the FTSE 100, while Nuvalent shares surged nearly 38% in premarket trading in the United States.
Under the terms of the agreement, GSK will launch a cash tender offer of $124 per share for Nasdaq-listed Nuvalent, representing a roughly 40% premium to the company's closing price on Monday.
Although the headline value of the transaction is $10.6 billion, GSK said its net investment would be approximately $9.4 billion after accounting for cash held on Nuvalent’s balance sheet.
The acquisition provides GSK with access to two late-stage lung cancer drug candidates and a third earlier-stage asset, giving the company multiple opportunities in one of the pharmaceutical industry's most lucrative treatment areas.
GSK expects the deal to contribute to revenue growth and strengthen core operating profit from next year.
The company also said the acquisition would help cushion the impact of patent expirations for dolutegravir, a key HIV treatment, between 2028 and 2030.
The transaction remains incremental to GSK’s broader target of generating more than £40 billion ($53.4 billion) in annual sales by 2031.
Oncology remains central to growth strategyThe acquisition marks another step in GSK’s effort to rebuild its oncology business after exiting the sector more than a decade ago.
In 2015, GSK completed a major asset swap with Swiss pharmaceutical company Novartis, selling its oncology division in exchange for Novartis’ vaccines business.
The companies also merged their consumer healthcare operations, with GSK later buying out Novartis’ stake for $13 billion.
Since then, GSK has steadily rebuilt its cancer portfolio through acquisitions and licensing agreements.
Previous deals have included purchases of oncology-focused companies such as Tesaro, Sierra Oncology, and IDRx.
Chief Executive Luke Miels described the company's approach as a gradual rebuilding process.
“Our strategy has been a brick-by-brick building approach,” Miels told reporters.
Unlike many of GSK’s recent acquisitions, which focused on single-product companies, the Nuvalent deal brings multiple assets under one transaction.
Miels said the acquisition remains consistent with GSK’s strategy of targeting companies with validated science that address shortcomings in existing treatments.
Despite the strategic rationale, analysts said the market reaction reflected concerns over the scale of the investment and the risks attached to Nuvalent’s pipeline.
Russ Mould, investment director at AJ Bell, said investors appear wary of the size of the acquisition and the premium GSK is paying.
“GSK is paying a hefty premium to get the deal over the line, and the two big lung cancer products flagged by Luke Miels still await regulatory approval,” Mould said.
“In rolling the dice on such a big transaction, he is undoubtedly taking a risk.”
Victoria Scholar, head of investment at Interactive Investor, echoed those concerns, noting that the deal is significantly larger than most of GSK’s previous acquisitions.
“GSK shares are down around 3% today, reflecting the fact that this is a mammoth deal even by GSK’s standards,” Scholar said.
She noted that the acquisition dwarfs previous oncology deals such as Tesaro and Sierra Oncology and carries execution risks given the reliance on regulatory approvals and future commercial success.
Despite investor caution, analysts acknowledged that GSK is securing a substantial oncology pipeline through a single transaction.
The company believes the acquisition will begin contributing to sales growth and earnings expansion from next year without disrupting its dividend policy.
Miels said GSK would need time to integrate Nuvalent but stressed that the company would retain the financial flexibility to pursue additional opportunities if attractive assets emerge.
1. M&A Action as GSK, ACN, and CRM Deploy Cash GSK (GSK +0.32%), Accenture (ACN +1.61%), and Salesforce (CRM 1.44%) announced major acquisitions, with GSK's $10.6 billion purchase of Nuvalent (NUVL 0.21%) its largest in a decade, as the M&A market continues to heat up.
Salesforce stock unchanged in pre-market trading: GSK stock fell around 2% in early trade, with the purchase enabling it to bolster its lung cancer pipeline. Salesforce's agreement to acquire M3ter paves the way for consumption billing expansion. "Whalar brings a creator capability that strengthens how we drive meaningful impact and growth for clients": Ndidi Oteh, CEO of Accenture Song, was upbeat as part of the purchase of Whalar, in a move designed to add scaled creator and influencer engagement. Accenture – like Salesforce, recommended by both Team Rule Breakers and Team Hidden Gems – was little changed ahead of the opening bell. 2. OpenAI Files Confidential S-1 for IPO OpenAI has confidentially submitted documentation for an IPO with the SEC, confirming the details a week after major rival Anthropic did the same, although the accompanying release statement said "we have not decided on timing yet."
"There are things we want to do that are likely easier as a private company": The statement didn't specify what actions it was referring to, although avoiding quarterly earnings pressure and limiting public disclosures could be factors. "It's a complicated set of trade-offs and this gives us the option to go public sooner if that ends up being best": The note alludes to pressure to go to market first relative to competitors, given the large amount of capital they hope to raise and the uncertainty of how multiple AI IPOs in quick succession could be received. 3. SpaceX Book Flooded with Whale Bids Bloomberg reports the SpaceX IPO is already oversubscribed ahead of the order deadline on Wednesday, with multiple institutional investors -- often referred to as whales -- submitting orders individually worth $10 billion or more.
Order book strength suggests it will be the largest IPO ever: Oversubscriptions would mean the target of raising $75 billion -- and valuing the company at about $1.8 trillion – would be validated, easily topping the $29.4 billion raised from Saudi Aramco back in 2019. "There can be little question that SpaceX is likely to rank among the most consequential IPOs of all time": Fool analyst Tim Beyers explained "that for the story to work out for common shareholders, SpaceX will need to effectively create space-based data centers that are either as advanced or more advanced than anything else coming from industry leaders." 4. Today's Take: How Total Is That Market?
Total addressable market is like the Pirate's Code: more guidelines than actual rules. Every company inflates its TAM to justify a richer valuation, so don't take the figures as gospel. But TAM frames the opportunity ahead.-- Nick Sciple Team Rule Breakers
One way I'll use TAM is to assess whether a company's growth momentum is sustainable or whether its management team's projections make sense.-- Matt Frankel Team Hidden Gems
5. Your Take On a scale of 1-10, how excited are you about the upcoming OpenAI IPO? What excites you or what concerns you about OpenAI as an investment?
Discuss with friends and family, or become a member to hear what your fellow Fools are saying!
This image and article was created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. The Motley Fool has positions in and recommends Accenture Plc and Salesforce. The Motley Fool recommends GSK and recommends the following options: long January 2028 $260 calls on Accenture Plc and short January 2028 $280 calls on Accenture Plc. The Motley Fool has a disclosure policy.
GSK GSK has agreed to acquire Nuvalent Inc. NUVL in a $10.6 billion cash deal, giving the British pharmaceutical company a bigger foothold in precision oncology as it works to rebuild its cancer drug portfolio. GSK will pay $124 per share, representing a 40% premium to Nuvalent's Monday closing price. The move marks the first major acquisition under CEO Luke Miels and signals a more aggressive push into lung cancer treatments after GSK returned to oncology in 2019.
Nuvalent is developing precisely targeted cancer therapies, including treatments for non-small-cell lung cancer patients with specific mutations that usually affect people who did not smoke. Two of the drugs GSK is acquiring are already in late-stage trials, with the FDA expected to decide on approval later this year. GSK said both medicines could become blockbuster products if approved, potentially adding fresh growth as vaccine sales have slowed and the company leans further into oncology, immunology, and HIV.
The transaction is expected to close by the third quarter, pending regulatory approvals, and will be funded mainly through new and existing debt facilities plus cash. GSK said the deal will not affect its guidance for the year or its credit rating, while Nuvalent could start contributing to revenue growth from 2027. Investors reacted cautiously, with GSK shares falling as much as 3% in early London trading, although the stock remains up around 23% over the past 12 months.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Nuvalent, Inc. (NASDAQ: NUVL) to GSK plc for $124.00 per share in cash. Halper Sadeh encourages Nuvalent shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Nuvalent and its board of directors violated the federal.
Nuvalent Inc (NASDAQ:NUVL) is soaring in premarket trading, up 38.9% to trade at $122.88, after London-based GSK agreed to acquire the cancer drug developer in an all-cash deal valued at approximately $10.6 billion. Under the terms of the agreement, GSK will pay $124 per share, representing a roughly 40% premium to Monday's closing price. The acquisition marks GSK's largest deal in more than a decade and expands its oncology portfolio.
Today's rally has NUVL stock set to open at fresh record highs. Prior to the buyout news, the shares had been struggling, down 12% in 2026 and nearly 16% over the last month.
Short sellers may be helping fuel some of this morning's outsized move. Short interest rose 4.9% in the most recent reporting period and now accounts for 7% of Nuvalent stock's available float. It would take shorts nearly nine days to cover, at NUVL's average pace of trading.
Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.
*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.
IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.
Stock futures are pointing to a higher open Tuesday as the market looks to extend its recovery from last week's losses; President Trump said last night that the U.S. and Iran are close to a "very, very good deal;" OpenAI has confidentially filed with the SEC for an IPO, but said in a statement it doesn't have a timeline for going public; Nuvalent shares are soaring after the drugmaker agreed to be acquired by British pharmaceutical giant GSK; and Vail Resorts shares are down after the company cut its outlook for the second time this year. Here's what you need to know today.
U.S. stocks were higher, with the Dow Jones index gaining over 300 points on Tuesday.
JM Smucker reported quarterly earnings of $2.77 per share which beat the analyst consensus estimate of $2.64 per share. The company reported quarterly sales of $2.268 billion which beat the analyst consensus estimate of $2.260 billion.
Smucker shares jumped 11% to $112.99 on Tuesday.
Here are some other big stocks recording gins in today’s session.
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Nuvalent, Inc. (NASDAQ: NUVL) related to its sale to GSK plc. Under the terms of the proposed transaction, Nuvalent shareholders are expected to receive $124.00 per share in cash. Is it a fair deal?
Click here for more info https://monteverdelaw.com/case/nuvalent-inc/. It is free and there is no cost or obligation to you.
NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:
Do you file class actions and go to Court?When was the last time you recovered money for shareholders?What cases did you recover money in and how much?
About Monteverde & Associates PC
Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.
Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America [email protected]
Tel: (212) 971-1341
Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
GSK GSK is experiencing a modest uptick in its stock price following the announcement of its acquisition of Nuvalent NUVL for $124 per share, totaling $10.6 billion. This strategic move aims to bolster GSK's late-stage lung cancer pipeline, featuring key assets such as the ROS1 inhibitor zidesamtinib and the ALK inhibitor neladalkib, along with an early-stage HER2-mutant NSCLC program. While GSK has reaffirmed its guidance for 2026 and its dividend policy, the deal comes with a significant 40% premium and is projected to be dilutive to core EPS until it becomes accretive in 2029.
Pipeline quality: The acquisition enhances GSK's credibility in lung cancer treatment with targeted therapies that address the limitations of current kinase inhibitors, focusing on efficacy, tolerability, brain metastases, and resistance. Near-term catalysts: Zidesamtinib is currently under FDA review, with a PDUFA date set for September 2026. Neladalkib also presents a potential launch opportunity if regulatory timelines are met. Strategic fit: This acquisition aligns with GSK’s strategy to expand into specialty medicines and oncology, integrating Nuvalent’s assets with GSK’s existing pipeline, including the Phase III B7-H3 ADC, Ris-Rez. Commercial opportunity: Analysts project that zidesamtinib and neladalkib could generate multibillion-dollar peak sales, justifying GSK's willingness to pay a premium for these assets. LOE bridge: GSK anticipates that this deal will enhance core operating profit during the 2028-2030 period when dolutegravir loses exclusivity, positioning NUVL as both a growth investment and a defensive strategy for the portfolio. Broader setup: This acquisition marks GSK’s largest in over a decade and reflects CEO Luke Miels' strategic vision to leverage M&A for scaling its oncology operations.The acquisition of Nuvalent is primarily focused on transforming GSK's medium-term growth profile in light of impending exclusivity pressures. The rationale is clear: GSK is securing two late-stage targeted lung cancer assets with potential regulatory catalysts in 2026, alongside an earlier-stage HER2-mutant NSCLC program that could enhance its oncology platform over time. Investor sentiment remains positive as management has reaffirmed its 2026 guidance and dividend policy, alleviating concerns about immediate instability from the deal. However, risks persist, as GSK is paying a substantial premium for assets that still depend on regulatory approval, successful launches, and commercial adoption to validate the investment. The critical test will be whether zidesamtinib and neladalkib can launch as scheduled and achieve sufficient scale to support revenue growth from 2027, while also mitigating the impact of dolutegravir's loss of exclusivity without straining the balance sheet or margins.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Key Takeaways GSK agreed to acquire Nuvalent for $124 per share in a deal valued at about $10.6 billion.GSK will add three NSCLC pipeline assets, including two candidates under FDA review.GSK expects the deal to aid revenue growth from 2027 and support long-term sales goals. GSK plc (GSK - Free Report) announced that it has agreed to acquire clinical-stage biotech Nuvalent (NUVL - Free Report) . Per the terms, the British drugmaker will acquire all outstanding shares of NUVL for $124 per share, valuing the deal at around $10.6 billion (~£8 billion).
Following the acquisition, GSK will add three pipeline candidates that are in clinical development. These include two candidates — ROS1 inhibitor zidesamtinib and ALK inhibitor neladalkib — that are currently being reviewed by the FDA as potential treatments for non-small cell lung cancer (NSCLC). Regulatory decisions on these filings are expected before this year’s end. Nuvalent's third pipeline asset, NVL-330, is a HER2 inhibitor currently being evaluated in an early-stage study for NSCLC. GSK will also acquire the preclinical portfolio, which consists of multiple programs.
GSK will also assume Nuvalent's existing revenue-sharing arrangements, including low-single-digit royalties payable to Royalty Pharma (RPRX - Free Report) and Deerfield
The transaction, expected to be completed in the third quarter, is subject to customary closing conditions and clearance from regulatory authorities. GSK expects to fund the deal using a combination of cash and debt.
GSK & NUVL Stock PerformancePost the announcement, shares of GSK were down 1% in pre-market trading today, while those of Nuvalent have jumped nearly 39%.
Year to date, GSK’s stock is up more than 3%, while Nuvalent is down 12%. In comparison, the industry has lost nearly 2% during this time frame.
Image Source: Zacks Investment Research
What Drives GSK’s Interest in Nuvalent?The acquisition strengthens GSK's growing oncology business by adding a portfolio of targeted therapies for genetically defined forms of NSCLC. The company believes Nuvalent's assets will enhance its precision oncology capabilities and expand its presence in the large and rapidly evolving NSCLC space.
GSK also sees the deal as complementary to risvutatug rezetecan, its experimental B7-H3-targeted antibody-drug conjugate (ADC) candidate being developed in a late-stage study for extensive-stage small-cell lung cancer. Management said the acquisition provides the company with a platform for expansion into the lung cancer space while creating additional growth opportunities within its oncology portfolio.
The transaction is expected to contribute to GSK's revenue growth beginning in 2027 and support its long-term objective of generating more than £40 billion in annual sales by 2031. Management expects the acquisition to be accretive to core operating profit from 2027 and to core EPS from 2029, inclusive of anticipated synergies.
Importantly, GSK said the deal is expected to strengthen core operating profit through the anticipated loss-of-exclusivity period for dolutegravir products between 2028 and 2030. This suggests that the company views Nuvalent's pipeline as a potential growth driver that could help offset future pressure on its HIV franchise.
Although GSK expects the transaction to result in low single-digit dilution to core EPS from 2026 through 2028, it maintained its previously issued 2026 guidance. The company expects 7-9% growth in core operating profit and core EPS, indicating that the near-term impact is not expected to materially affect its earnings outlook.
The Nuvalent acquisition marks GSK's third deal in 2026. Earlier this year, the company expanded its respiratory, immunology and inflammation pipeline through the acquisitions of clinical-stage company RAPT Therapeutics and private biotech 35Pharma. These transactions underscore GSK's continued focus on strengthening its pipeline through targeted acquisitions of clinical-stage biotechnology companies.
GSK’s Zacks RankGSK currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
The proposed transactions may contain terms that could limit superior competing offers.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nuvalent, Inc. (NASDAQ: NUVL)’s sale to GSK plc for $124.00 per share in cash. If you are a Nuvalent shareholder, click here to learn more about your rights and options.
SUNation Energy, Inc. (NASDAQ: SUNE)’s merger with Suniva. Upon closing of the proposed transaction, SUNation shareholders are expected to own approximately 1.8% of the combined company. If you are a SUNation shareholder, click here to learn more about your rights and options.
Organon & Co. (NYSE: OGN)’s sale to Sun Pharmaceutical Industries Limited for $14.00 per share. If you are an Organon shareholder, click here to learn more about your legal rights and options.
Taylor Morrison Home Corporation (NYSE: TMHC)’s sale to Berkshire Hathaway Inc. for $72.50 per common share in cash. If you are a Taylor Morrison shareholder, click here to learn more about your legal rights and options.
On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060 [email protected] [email protected]
https://www.halpersadeh.com
GSK PLC's (LSE:GSK, NYSE:GSK) $10.6 billion (£8bn) acquisition of US biotech Nuvalent has achieved something unusual in large pharmaceutical M&A: analysts broadly agree it makes sense.
The debate is less about whether the deal is strategically sound and more about how much upside remains after shelling out a chunky amount for two relatively mature assets.
The transaction brings two late-stage lung cancer medicines, neladalkib and zidesamtinib, both targeting genetically defined forms of non-small cell lung cancer and both expected to face regulatory decisions within months.
For GSK, the immediate attraction is to further swell the oncology franchise that former boss Emma Walmsley spent years rebuilding to help calm investor worries over the eventual loss of exclusivity on its HIV portfolio.
UBS called the acquisition a "strong strategic fit", arguing the drugs could generate combined peak sales of $3.75 billion and help smooth the earnings drag from HIV patent expiries between 2028 and 2031.
Shore Capital was even more enthusiastic, describing the deal as laying the foundations for a lung cancer franchise while further weakening the bear case centred on the HIV patent cliff.
Deutsche Bank was more measured, with analyst Emmanuel Papadakis noting that GSK is paying roughly three times consensus peak sales forecasts for assets targeting well-understood markets. That looks reasonable rather than cheap.
The central question is whether GSK is buying future growth or merely bringing forward revenue it could already see coming.
"It is hard to make a case for much hidden value in the acquisition," said Papadakis.
He said the two main assets bring "relatively derisked and imminent oncology revenue streams", though the targets are in "familiar if somewhat derivative and crowded spaces".
Pluses for Papadakis are the "modest premium" paid to accelerate the oncology rebuild and nudge towards the 2031 revenue target.
"In that regard, the acquisition seems totally reasonable overall and we also thought the company did a reasonably cogent job of outlining the case for some asset differentiation," he said, before countering that the key ALKAZAR trial "will not read out for some years to fully prove the deal".
Deutsche's 'hold' and 1,900p target were unchanged, as were UBS's 'neutral' rating and 1,940p target.
Shore Cap's Sean Conroy raised his target price to 2,600p from 2,500p and reiterated his 'buy' recommendation, saying the shares on his revised numbers imply a 13 2027 P/E ratio, "which looks undemanding considering where peers trade" and keeping GSK as his preferred UK pharma name, over AstraZeneca.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Ademi LLP is investigating Nuvalent (NASDAQ: NUVL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc.
Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.
Nuvalent stockholders will receive $124 per share and the aggregate equity value of the transaction is approximately $10.6 billion. Nuvalent insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Nuvalent by imposing a significant penalty if Nuvalent accepts a competing bid. We are investigating the conduct of the Nuvalent board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders PR Newswire
MILWAUKEE, June 10, 2026
, /PRNewswire/ -- Ademi LLP is investigating Nuvalent (NASDAQ: NUVL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc.
Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.
Nuvalent stockholders will receive $124 per share and the aggregate equity value of the transaction is approximately $10.6 billion. Nuvalent insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Nuvalent by imposing a significant penalty if Nuvalent accepts a competing bid. We are investigating the conduct of the Nuvalent board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-nuvalent-inc-is-obtaining-a-fair-price-for-public-shareholders-302796643.html
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Nuvalent will receive $124.00 in cash for each share of Nuvalent that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.
SummaryCompaniesDeal deepens oncology push under CEO Luke MielsBoosts investor confidence GSK could achieve 2031 sales targetInvestors say GSK may need more deals to catch up with rivals in oncologyLONDON, June 11 (Reuters) - GSK's (GSK.L), opens new tab record $10.6 billion deal for U.S. company Nuvalent (NUVL.O), opens new tab will accelerate the British drugmaker's rebuild of its cancer drug business as it seeks to fend off competition from bigger rivals AstraZeneca (AZN.L), opens new tab and Roche (ROPC.S), opens new tab.
The takeover bid, codenamed Nashville, is GSK's biggest acquisition to date and brings with it two lung cancer treatments that could be approved in the U.S. this year. The deal is expected to close in the third quarter.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
It ties in with the plans of CEO Luke Miels, who took office at the start of the year, to expand the drugmaker's presence in oncology, a business it left a decade ago in a more than $16 billion asset swap with Novartis.
The deal should also help to offset the impact of patent cliffs later this decade that are likely to dent sales of HIV drug dolutegravir. GSK's total drug sales are estimated to be £34 billion ($45.53 billion) this year, analysts say.
The Nuvalent bid builds on previously smaller moves into oncology, including a $5.1 billion deal for Tesaro in 2018, a nearly $2 billion purchase of Sierra Oncology and multi-billion-dollar licensing deals.
"Our strategy has been a brick-by-brick building approach," Miels told a group of journalists on Tuesday after the Nuvalent deal was announced.
British drugmaker has been rebuilding it's cancer drug pipeline through acquisitions and licensing deals in recent years'A VERY LARGE BRICK'James Eugene, analyst at GSK-shareholder Verso Investment Management, said Nuvalent was "a very large brick" in the overall rebuild.
Other investors agreed.
"The scale is obviously much larger than what GSK has done historically," said Elena Meng, portfolio manager at Gabelli Funds, which holds U.S.-listed GSK depositary receipts, adding the oncology strategy itself was established.
"What's new is the size of the commitment."
A person close to the deal said that there had been competition for Nuvalent, which in part explained the 40% premium to the biotech's closing price before the agreement was announced.
The company had been on the radar of large drugmakers for at least 18 months because it was one of only a few with late-stage oncology assets nearing approval, the person said, asking not to be named because they were not authorised to speak publicly on the issue.
REVERSING A STRATEGIC MISSTEPSome investors said the return to oncology undid a strategic misstep under former CEO Andrew Witty when the company left the sector to focus on vaccines, respiratory drugs and consumer health.
The shift back began under Miels' predecessor Emma Walmsley, who took the top role in 2017.
"It was definitely a mistake in 2015 to sell the oncology franchise," Markus Manns, portfolio manager at GSK shareholder Union Investment, said.
He added the Nuvalent deal brought de-risked products that together should be able to achieve $3 billion to $4 billion peak sales, helping counter the HIV treatments' loss of exclusivity. It would also help the company to hit its £40 billion sales target by 2031.
GSK does not expect to compete with Merck (MRK.N), opens new tab, AstraZeneca or Roche across all of oncology, but views it as a potential area of growth. The Nuvalent deal would add two late-stage drugs to its portfolio.
"A specialty business without an oncology component is not a complete proposition," the drugmaker's chief scientific officer Tony Wood told Reuters before the deal.
GSK exited the market for cancer therapies in 2015 and is making a comeback after years of shareholders frustration with the company's R&D performanceGSK now needs to show the lung cancer treatments, which target ROS1- and ALK-positive mutations, can compete with more-established rival drugs from U.S. drugmaker Pfizer (PFE.N), opens new tab and Switzerland's Roche, as well as proving their tolerability.
Analysts at Barclays said the acquisition made sense, but cautioned that neither asset appeared to have "mega blockbuster" status.
GSK expects that small patient groups could become sizeable opportunities if the therapies keep younger, active patients on treatment for years with fewer side effects than existing medicines.
Ketan Patel, fund manager at London-based family investment office Whitefriars, said that while the Nuvalent deal was an important step, GSK needs to do more deals to truly compete in the oncology space.
"GSK is playing catchup," he said, referring to Roche and Merck's leads in the space.
"I think they are way behind and unlikely to catch up to those names, and will in all probability have to pay up to play in the same arena."
GSK is aiming to grow its presence in oncology with newer drugs but might need to do more to compete with established rivals AstraZeneca and Roche($1 = 0.7468 pounds)
Reporting by Bhanvi Satija and Maggie Fick in London and Sabrina Valle in New York; Editing by Adam Jourdan and Barbara Lewis
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Bhanvi is a London-based reporter covering European pharmaceutical companies and the healthcare industry. She previously covered U.S. health and pharma firms, with a focus on the new weight loss drugs that are transforming the obesity treatment space. Her coverage includes a trend piece on the underuse of their weight-loss drugs among men, increased interest in therapies being developed for preservation of lean mass, and a scoop on gene therapy maker Sarepta defying an FDA order to stop shipping its muscular dystrophy treatment.
NY-based correspondent reporting on some of the largest deals in Healthcare and Industrials. Previously based in Houston, covering global operations of U.S. oil majors. Sabrina has a two-decade career in Business reporting, with a strong background in source-based enterprise and investigations. She previously worked at Bloomberg, Washington Post and has been based in Rio and D.C. covering large corporations, including finance, corruption and geopolitics.
The sudden $10.6 billion acquisition of Nuvalent NASDAQ: NUVL by GSK NYSE: GSK violently shatters a lingering mergers and acquisitions (M&A) drought across the mid-cap biotechnology sector.
The all-cash buyout at $124 per share represents a roughly 40% premium over recent closing levels and a 26% premium over a 30-day volume-weighted average price.
Get Nuvalent alerts:
This transaction, which is expected to close in Q3 2026, could immediately recalibrate a valuation floor for targeted kinase inhibitors. Big Pharma is aggressively deploying capital. A late-2020s patent cliff is rapidly transitioning from a distant theoretical threat into an active catalyst, forcing cash-rich incumbents to buy their way out of impending margin compression.
Peak Clinical Probability Over FundamentalsNuvalent Today
$123.20 -0.25 (-0.20%)
As of 11:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$71.13▼
$123.62Price Target$131.15
Retail value screens often miss the structural realities that dictate biotechnology buyout valuations.
Over the trailing 12 months, Nuvalent posted a $425.38 million net loss, generated zero commercial revenue, and reported an earnings per share loss of $6.06.
Traditional fundamental analysis flags these metrics as highly speculative and largely uninvestable; however, institutional acquirers operate on an entirely different valuation matrix.
Large-cap pharmaceutical entities assign enterprise value to clinical-stage pure-plays less on trailing fundamentals and more on peak clinical probability, de-risked target validation, and out-year blockbuster potential.
Nuvalent brings two highly selective late-stage assets targeting non-small cell lung cancer. Zidesamtinib is a ROS1 inhibitor, while neladalkib is an ALK inhibitor. Both therapies hold FDA Breakthrough Therapy and Orphan Drug Designations, with target Prescription Drug User Fee Act dates of September 18, 2026, and November 27, 2026, respectively.
GSK is paying a premium for clear regulatory line-of-sight and potential post-approval market opportunities, which can outweigh standard trailing multiples.
A $10.6 Billion Bridge Through the Patent CliffGSK Today
$53.11 +0.25 (+0.48%)
As of 11:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$35.45▼
$61.69Dividend Yield3.41%
P/E Ratio13.80
Price Target$53.00
This acquisition architecture relies heavily on corporate defense.
GSK trades at a conservative price-to-earnings (P/E) ratio of 13.3, generates substantial free cash flow, and yields an attractive dividend yield of roughly 3.5%.
Behind these healthy current metrics sits a looming structural gap.
An impending loss of exclusivity for dolutegravir, GSK's foundational HIV franchise, threatens to erode operating profit margins heavily between 2028 and 2030. Dolutegravir generates billions in reliable annual cash flow, making its patent expiration a systemic threat to GSK's long-term balance sheet.
Under the direction of Chief Executive Officer Luke Miels, this $10.6 billion allocation operates as a direct revenue bridge. As an entire sector, the pharmaceutical industry faces a multibillion-dollar revenue gap by the end of this decade due to expiring patents on legacy blockbuster drugs. Internal research and development simply cannot fill this void fast enough to satisfy institutional shareholders.
Cash reserves hoarded during a high-interest-rate environment must now be aggressively deployed to acquire phase 3 or pre-approval assets capable of immediate commercialization and rapid scale.
Trapping the Bears in a Biotech Short SqueezeMechanics driving this buyout highlight a critical vulnerability for institutional bears positioned in pre-revenue biotechnology assets.
Nuvalent has about 5.2 million shares sold short, representing approximately 7% of total float. Bears calculated a 9-day-to-cover ratio, betting heavily on regulatory delays, high cash burn, or commercial execution risks inherent in launching two targeted therapies simultaneously.
Recent insider transactions may have provided false confirmation for a prevailing short thesis. Nuvalent insiders executed significant equity liquidations over the trailing three months, unloading $19.2 million in shares. This included a $1.12 million sale by Nuvalent's Chief Financial Officer and additional distributions by core Nuvalent insiders just days before a final acquisition announcement. Bears incorrectly interpreted routine liquidity events or scheduled program sales as a lack of executive confidence.
A $10.6 billion buyout triggered immediate forced liquidations among those trapped offside. Nuvalent shares gapped up over 39% intraday, crossing $123.25 in a textbook short squeeze. Institutional anchors like Perceptive Advisors, Janus Henderson Group, and Commodore Capital absorbed early liquidity and fully validated their long-term conviction in Nuvalent's clinical data.
Roche and Pfizer May Need to Fish for New Assets DefensivelyThis transaction could fundamentally alter a competitive matrix for legacy oncology franchises.
Nuvalent's pipeline is engineered specifically to bypass standard-of-care drug resistance and minimize central nervous system toxicity in non-small cell lung cancer patients. This technological leap poses a potential commercial threat to established sector participants that rely on older kinase-inhibitor science.
Incumbents relying on legacy lung cancer portfolios face acute obsolescence risks. Therapeutics currently dominating a lucrative lung cancer space, such as Alecensa, Rozlytrek, Lorbrena, and Xalkori, now face a potentially superior tolerability profile backed by GSK's global commercialization engine.
Competing pharmaceutical giants, including Roche OTCMKTS: RHHVF and Pfizer NYSE: PFE, could now be forced into a defensive posture. Roche and Pfizer can no longer afford to stand by as mid-cap oncology developers mature independently. A rapid deployment of GSK's capital may force industry peers to execute counter-acquisitions to protect market share in targeted oncology.
Scouting the Next Unpartnered CatchA remaining pool of unpartnered, high-efficacy oncology pure-plays becomes an immediate focus for institutional speculators. Companies developing targeted therapies with clear mechanisms of action, especially those capable of overcoming resistance mutations in solid tumors, are directly in the crosshairs. Large-cap pharmaceutical enterprises need these assets to survive an impending patent cliff.
Investors should seek to identify clinical-stage entities operating with large cash runways. For example, before its sudden acquisition, Nuvalent maintained a robust current ratio of 16.14, a level of liquidity that effectively insulated the clinical-stage entity from the need to pursue near-term dilutive equity financing.
This degree of financial sovereignty forces institutional predators to offer aggressive premiums, as target boards remain under less structural duress to accept discounted bids. When a fortified balance sheet intersects with heavy bearish positioning, the resulting architecture mirrors the Nuvalent squeeze.
As Big Pharma identifies pipeline assets capable of bridging impending revenue gaps, these technical mispricing voids resolve with extreme volatility, providing massive capital appreciation potential for speculators positioned ahead of a systemic sector rotation.
Should You Invest $1,000 in Nuvalent Right Now?Before you consider Nuvalent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvalent wasn't on the list.
While Nuvalent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Graphic Packaging Holding Company (NYSE: GPK) between February 4, 2025 and February 2, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Graphic Packaging securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Graphic Packaging class action, go to https://rosenlegal.com/submit-form/?case_id=64523 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Graphic Packaging was experiencing, inter alia, significant inventory management issues, as well as significantly reduced demand and volumes and increased costs; (2) defendants downplayed the true scope and severity of the foregoing issues, which were likely to, and did, have a material negative impact on Graphic Packaging’s business and financial results; (3) defendants likewise overstated the strength and sustainability of Graphic Packaging’s business model and operations, as well as its ability to weather ongoing macroeconomic headwinds; (4) accordingly, Graphic Packaging’s previously issued full year 2025 financial guidance was unreliable and/or unrealistic; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Graphic Packaging class action, go to https://rosenlegal.com/submit-form/?case_id=64523 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
Deadline Alert: GPK Investors Who Lost Money Between February 2025 and February 2026 Must Act by July 6, 2026 to Seek Lead Plaintiff Appointment in Graphic Packaging Securities Class Action
, /PRNewswire/ -- IMPORTANT DATE: July 6, 2026. Investors who purchased Graphic Packaging Holding Company (NYSE: GPK) securities between February 4, 2025 and February 2, 2026 and wish to seek appointment as lead plaintiff must file a motion with the Court by this date. Start your claim now before the deadline. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.
GPK shares declined 15.57%, 8.66%, and 15.97% as successive disclosures revealed further corrective information during the Class Period. The lead plaintiff deadline is July 6, 2026.
What is a Lead Plaintiff?
Under the Private Securities Litigation Reform Act of 1995 ("PSLRA"), the Court appoints a lead plaintiff to represent the interests of all class members. The lead plaintiff selects counsel, oversees litigation strategy, and ensures the case is prosecuted in the best interests of the class. Any investor who purchased GPK securities during the Class Period and suffered losses may apply.
Lead Plaintiff Facts
Key information for GPK investors considering lead plaintiff appointment:
The lead plaintiff is typically the investor or group of investors with the largest financial interest in the relief sought by the class You do not need to pay any fees or costs upfront to serve as lead plaintiff; securities class actions are handled on a contingency basis Lead plaintiffs have direct input on settlement decisions and case strategy In the GPK action, applicants must demonstrate purchases of GPK securities between February 4, 2025 and February 2, 2026 at prices the complaint alleges were artificially inflated Institutional investors, pension funds, and individual shareholders are all eligible to apply Competing motions are consolidated and the Court selects the most adequate plaintiff based on statutory criteria Post-Deadline Procedures
After July 6, 2026, the Court will review all lead plaintiff motions and schedule a hearing to determine the most adequate plaintiff. This process typically takes several weeks. During this period, the case continues, and all class members retain their rights regardless of whether they applied for lead plaintiff.
Absent Class Member Rights
Investors who do not apply for lead plaintiff by July 6, 2026 are not excluded from the case. Absent class members retain the right to participate in any recovery obtained on behalf of the class. No action is required to preserve your rights as a class member. The deadline applies only to those seeking the lead plaintiff role.
"The lead plaintiff process is designed to ensure the class is represented by shareholders with substantial interests in the outcome. In the Graphic Packaging action, where alleged misrepresentations about inventory management and business sustainability contributed to a decline of over 50% in share value, lead plaintiff selection will be an important step toward accountability." -- Joseph E. Levi, Esq.
Find out if you qualify to recover losses or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
Frequently Asked Questions About the GPK Lawsuit
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: How do I know if I lost enough money to be the lead plaintiff? A: There is no minimum loss threshold. Courts appoint the investor with the largest provable loss who is willing and able to represent the class adequately. Contact Levi & Korsinsky before July 6, 2026 to evaluate.
Q: What do GPK investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as a class member.
Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery.
Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: What documents do I need to make a claim? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
NEW YORK, June 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Graphic Packaging Holding Company (“Graphic Packaging” or the “Company”) (NYSE: GPK) investors of the July 6, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.
Should You Join The Graphic Packaging Class Action Lawsuit:
Do you, or did you, own shares of Graphic Packaging Holding Company (NYSE: GPK)?Did you purchase your shares between February 4, 2025 and February 2, 2026, inclusive?Did you lose money in your investment in Graphic Packaging Holding Company?
If you purchased or acquired Graphic Packaging securities, and/or would like to discuss your legal rights and options please visit Graphic Packaging Holding Company Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].
If you wish to serve as lead plaintiff for the Class, you must file papers by July 6, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About The Lawsuit:
A lawsuit was filed on behalf of investors (the “Class”) who purchased or acquired the securities of Graphic Packaging between February 4, 2025 and February 2, 2026, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.
The lawsuit alleges that defendants made materially false and misleading statements and omissions regarding the Company’s business operations, growth prospects, and financial stability. As a result of these alleged misrepresentations, Graphic Packaging securities traded at artificially inflated prices during the Class Period. When the truth was disclosed, investors allegedly suffered significant losses.
About Bernstein Liebhard:
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Graphic Packaging To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Graphic Packaging between February 4, 2025 and February 2, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - June 10, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Graphic Packaging Holding Company ("Graphic Packaging" or the "Company") (NYSE: GPK) and reminds investors of the July 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Graphic Packaging was experiencing, inter alia, significant inventory management issues, as well as significantly reduced demand and volumes and increased costs; (2) Defendants downplayed the true scope and severity of the foregoing issues, which were likely to, and did, have a material negative impact on the Company's business and financial results; (3) Defendants likewise overstated the strength and sustainability of the Company's business model and operations, as well as its ability to weather ongoing macroeconomic headwinds; (4) accordingly, the Company's previously issued FY 2025 financial guidance was unreliable and/or unrealistic; and (5) as a result, Defendants' public statements were materially false and misleading at all relevant times.
The truth began to emerge on May 1, 2025, when Graphic Packaging issued a press release reporting its first quarter ("Q1") 2025 financial results. Among other results, the press release reported Q1 non-GAAP EPS of $0.51, missing consensus estimates by $0.07, and revenue of $2.12 billion, representing a 6.2% year-over-year decline, and missing consensus estimates by $10 million. The press release further revealed that the Company had negatively revised its previously issued FY 2025 net sales outlook to a range of $8.2 billion to $8.5 billion, significantly down from its prior guidance of $8.7 billion to $8.9 billion; its adjusted EBITDA outlook to a range of $1.4 billion to $1.6 billion, significantly down from its prior guidance of $1.68 billion to $1.78 billion; and its adjusted EPS outlook to a range of $1.75 to $2.25, significantly down from its prior guidance of $2.53 to $2.78. The Company blamed the negatively revised guidance on "an expectation of a 2% volume decline and $80 million of input cost inflation at the midpoint", as well as "higher macroeconomic and consumer spending uncertainty."
On this news, Graphic Packaging's stock price fell $3.94 per share, or 15.57%, to close at $21.37 per share on May 1, 2025.
On December 8, 2025, Graphic Packaging issued a press release announcing that it "plans to accelerate certain inventory reduction plans into the fourth quarter that were originally planned for 2026", and that "production curtailment is expected to impact fourth quarter operating results by $15 million, which is in addition to the $15 million relating to" certain earlier-announced curtailments. The Company further revealed that it had negatively revised its FY 2025 financial guidance again, now expecting its adjusted EBITDA "to be in the range of $1.38 billion to $1.43 billion"-significantly below its previously revised guidance of $1.4 billion to $1.45 billion-and adjusted EPS "to be in the range of $1.75 to $1.95"-significantly below its previously revised guidance of $1.80 to $2.00.
In a separate press release issued the same day, Graphic Packaging announced that Defendant Doss had "mutually agreed with [its] Board of Directors to step down from his role [as President and CEO] and as a director effective December 31, 2025."
Following these disclosures, Graphic Packaging's stock price fell $1.35 per share, or 8.66%, to close at $14.23 per share on December 9, 2025.
Then, on February 3, 2026, Graphic Packaging issued a press release reporting its fourth quarter ("Q4") and FY 2025 financial results. Among other results, Graphic Packaging reported Q4 non-GAAP EPS of $0.29, missing consensus estimates by $0.06. The Company attributed its disappointing Q4 2025 earnings results to, inter alia, lower volumes, increased costs, and inventory reduction. Further, Graphic Packaging projected a meaningful decline in adjusted EBITDA in 2026, citing "a $130 million negative impact from actions taken to reduce inventory and generate [FCF], an approximately $100 million accrual (non-cash in 2026) for a return to more normal incentive compensation, January weather and production impacts, and other largely offsetting operating items."
In the same press release, Graphic Packaging's new President and CEO, Robbert Rietbroek, announced that he had "initiated a comprehensive review of our organization structure, operations, and footprint," among other aspects of the Company's business, thereby confirming the weakness and unsustainability of its present business model and operations.
On this news, Graphic Packaging's stock price fell $2.36 per share, or 15.97%, to close at $12.42 per share on February 3, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Graphic Packaging's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Graphic Packaging class action, go to www.faruqilaw.com/GPK or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300754
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - June 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Graphic Packaging Holding Company (NYSE: GPK) between February 4, 2025 and February 2, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Graphic Packaging securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Graphic Packaging class action, go to https://rosenlegal.com/submit-form/?case_id=64523 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Graphic Packaging was experiencing, inter alia, significant inventory management issues, as well as significantly reduced demand and volumes and increased costs; (2) defendants downplayed the true scope and severity of the foregoing issues, which were likely to, and did, have a material negative impact on Graphic Packaging's business and financial results; (3) defendants likewise overstated the strength and sustainability of Graphic Packaging's business model and operations, as well as its ability to weather ongoing macroeconomic headwinds; (4) accordingly, Graphic Packaging's previously issued full year 2025 financial guidance was unreliable and/or unrealistic; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Graphic Packaging class action, go to https://rosenlegal.com/submit-form/?case_id=64523 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300984
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Graphic Packaging Holding Company ("Graphic Packaging" or "the Company") (NYSE: GPK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of GPK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: February 4, 2025 to February 2, 2026
DEADLINE: July 6, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Graphic Packaging downplayed the severity of reduced demand, higher costs, and inventory management struggles. Based on these facts, Graphic Packaging's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Graphic Packaging Holding Company ("Graphic Packaging" or "the Company") (NYSE: GPK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between February 4, 2025 and February 2, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 6, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Graphic Packaging suffered from inventory management problems, increased costs and reduced demand. The Company downplayed the severity of these issues despite the fact they would have a material impact on its financial performance. The Company overstated the strength of its business model. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Graphic Packaging, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
GPK's CEO and CFO Personally Certified Financial Statements While Allegedly Concealing Inventory Mismanagement and Demand Deterioration That Erased Over 50% of Shareholder Value
, /PRNewswire/ -- SueWallSt alerts investors in Graphic Packaging Holding Company (NYSE: GPK) that two senior executives are named as individual defendants in a securities class action covering purchases between February 4, 2025 and February 2, 2026. Find out if you qualify to recover losses or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.
GPK shares fell from over $25 to $12.42 per share across three corrective disclosures, a cumulative decline exceeding 50%. The Court has set July 6, 2026 as the deadline to apply for lead plaintiff appointment.
The Named Individual Defendants
Michael P. Doss served as President, CEO, and Director of Graphic Packaging at all relevant times until January 1, 2026. During the Class Period, Doss sold nearly 1.6 million shares of Company stock, receiving over $7 million in proceeds, the lawsuit asserts.
Stephen R. Scherger served as Executive Vice President and Chief Financial Officer at all relevant times until November 7, 2025. Scherger sold 65,529 shares during the Class Period, receiving nearly $1.8 million, the action claims.
Section 20(a) Control Person Framework
The complaint charges both executives as "controlling persons" under Section 20(a) of the Securities Exchange Act of 1934. The action contends that Doss and Scherger: Possessed the power and authority to control the contents of Graphic Packaging's SEC filings, press releases, and market communications Were provided with copies of SEC filings and press releases prior to or shortly after their issuance and had the ability to prevent issuance or cause corrections Had access to material non-public information about inventory management failures, reduced demand, and increased costs that was being concealed from the investing public Sold a combined $8.8 million in personal GPK stock while the Company's shares allegedly traded at artificially inflated prices Sarbanes-Oxley Certification Obligations
Both executives signed SOX certifications appended to the Company's Form 10-K for FY 2024 and subsequent quarterly reports on Forms 10-Q. These certifications stated that each filing "does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made . . . not misleading" and that "the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows" of the Company.
The complaint alleges these certifications were false when made because both executives knew Graphic Packaging was experiencing significant inventory management problems, declining demand, and rising costs that rendered the Company's FY 2025 guidance unreliable.
Speak with an attorney about your options in this case or call (888) SueWallSt.
Scienter Allegations
"Corporate officers have a duty to ensure their companies' public statements are accurate and complete. When executives personally certify SEC filings under Sarbanes-Oxley, they assume direct responsibility for material omissions that harm investors." -- Joseph E. Levi, Esq.
The complaint asserts that both defendants' personal stock sales, totaling $8.8 million during the Class Period, further support the inference that they knew the Company's public statements were misleading at the time they were made.
Submit your information to join the recovery or contact Joseph E. Levi, Esq. at (888) SueWallSt.
WHY SUEWALLST -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, SueWallSt is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.
Frequently Asked Questions About the GPK Lawsuit
Q: Who are the defendants named in the GPK lawsuit? A: The complaint names Graphic Packaging Holding Company and individual defendants including former CEO Michael P. Doss and former CFO Stephen R. Scherger, who signed SEC filings and certified financial disclosures under Sarbanes-Oxley during the Class Period.
Q: What is the GPK class action lawsuit about? A: A securities class action has been filed against Graphic Packaging (NYSE: GPK) alleging materially false and misleading statements between February 4, 2025 and February 2, 2026. Shares fell over 15.57%, then 8.66%, followed by a final 15.97% after the truth was revealed through three corrective disclosures, causing significant losses for shareholders.
Q: What do GPK investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at [email protected] or (888) SueWallSt. No immediate action is required to remain eligible as a class member.
Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: What if I already sold my GPK shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.
Q: What is the GPK lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is July 6, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.
Q: Can I join a different law firm's lawsuit instead? A: Multiple firms often file competing complaints. The court consolidates and appoints a single lead counsel. Contacting SueWallSt before July 6, 2026 ensures your losses are considered.
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Graphic Packaging Holding Company ("Graphic Packaging" or the "Company") (NYSE: GPK) and certain of its former officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-03790, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Graphic Packaging securities between February 4, 2025 and February 2, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its former top officials.
If you are an investor who purchased or otherwise acquired Graphic Packaging securities during the Class Period, you have until July 6, 2026, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
[Click here for information about joining the class action]
Graphic Packaging, together with its subsidiaries, designs, produces, and sells consumer packaging products. Its customers include businesses in the food, foodservice, beverage, household, and other consumer product industries in the Americas, Europe, and the Asia Pacific. The Company sells its products through sales offices, as well as through broker arrangements with third parties.
At all relevant times, Defendants touted the purported strength and stability of Graphic Packaging's business model and operations, as well as its purported ability to deliver on its cost and inventory reduction, free cash flow (FCF"), and profitability goals, notwithstanding ongoing and persistent market headwinds challenging the Company's and its customers' businesses.
Indeed, in February 2025, despite its President and Chief Executive Officer ("CEO"), Defendant Michael P. Doss ("Doss"), acknowledging "unusual volume challenges for the industry and our customers" over the past several years, Graphic Packaging forecasted full year ("FY") 2025 net sales, adjusted EBITDA, and adjusted earnings per share ("EPS") of $8.7 billion to $8.9 billion, $1.68 billion to $1.78 billion, and $2.53 to $2.78, respectively, excluding foreign exchange impacts. Defendant Doss attributed the Company's ability to weather the aforementioned headwinds to its overall business model and operations, asserting that Defendants would continue to "build on" the Company's "consisten[t]" and "profit[able]" and "strong and steady" results in 2025.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Graphic Packaging was experiencing, inter alia, significant inventory management issues, as well as significantly reduced demand and volumes and increased costs; (ii) Defendants downplayed the true scope and severity of the foregoing issues, which were likely to, and did, have a material negative impact on the Company's business and financial results; (iii) Defendants likewise overstated the strength and sustainability of the Company's business model and operations, as well as its ability to weather ongoing macroeconomic headwinds; (iv) accordingly, the Company's previously issued FY 2025 financial guidance was unreliable and/or unrealistic; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.
The truth began to emerge on May 1, 2025, when Graphic Packaging issued a press release reporting its first quarter ("Q1") 2025 financial results. Among other results, the press release reported Q1 non-GAAP EPS of $0.51, missing consensus estimates by $0.07, and revenue of $2.12 billion, representing a 6.2% year-over-year decline, and missing consensus estimates by $10 million. The press release further revealed that the Company had negatively revised its previously issued FY 2025 net sales outlook to a range of $8.2 billion to $8.5 billion, significantly down from its prior guidance of $8.7 billion to $8.9 billion; its adjusted EBITDA outlook to a range of $1.4 billion to $1.6 billion, significantly down from its prior guidance of $1.68 billion to $1.78 billion; and its adjusted EPS outlook to a range of $1.75 to $2.25, significantly down from its prior guidance of $2.53 to $2.78. The Company blamed the negatively revised guidance on "an expectation of a 2% volume decline and $80 million of input cost inflation at the midpoint", as well as "higher macroeconomic and consumer spending uncertainty."
On this news, Graphic Packaging's stock price fell $3.94 per share, or 15.57%, to close at $21.37 per share on May 1, 2025.
On December 8, 2025, Graphic Packaging issued a press release announcing that it "plans to accelerate certain inventory reduction plans into the fourth quarter that were originally planned for 2026", and that "[p]roduction curtailment is expected to impact fourth quarter operating results by $15 million, which is in addition to the $15 million relating to" certain earlier-announced curtailments. The Company further revealed that it had negatively revised its FY 2025 financial guidance again, now expecting its adjusted EBITDA "to be in the range of $1.38 billion to $1.43 billion"—significantly below its previously revised guidance of $1.4 billion to $1.45 billion—and adjusted EPS "to be in the range of $1.75 to $1.95"—significantly below its previously revised guidance of $1.80 to $2.00.
In a separate press release issued the same day, Graphic Packaging announced that Defendant Doss had "mutually agreed with [its] Board of Directors to step down from his role [as President and CEO] and as a director effective December 31, 2025."
Following these disclosures, Graphic Packaging's stock price fell $1.35 per share, or 8.66%, to close at $14.23 per share on December 9, 2025.
Then, on February 3, 2026, Graphic Packaging issued a press release reporting its fourth quarter ("Q4") and FY 2025 financial results. Among other results, Graphic Packaging reported Q4 non-GAAP EPS of $0.29, missing consensus estimates by $0.06. The Company attributed its disappointing Q4 2025 earnings results to, inter alia, lower volumes, increased costs, and inventory reduction. Further, Graphic Packaging projected a meaningful decline in adjusted EBITDA in 2026, citing "a $130 million negative impact from actions taken to reduce inventory and generate [FCF], an approximately $100 million accrual (non-cash in 2026) for a return to more normal incentive compensation, January weather and production impacts, and other largely offsetting operating items."
In the same press release, Graphic Packaging's new President and CEO, Robbert Rietbroek, announced that he had "initiated a comprehensive review of our organization structure, operations, and footprint," among other aspects of the Company's business, thereby confirming the weakness and unsustainability of its present business model and operations.
On this news, Graphic Packaging's stock price fell $2.36 per share, or 15.97%, to close at $12.42 per share on February 3, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Graphic Packaging Holding Company ("Graphic Packaging" or the "Company") (NYSE: GPK).
IF YOU SUFFERED A LOSS ON YOUR GRAPHIC PACKAGING INVESTMENTS, CLICK HERE BEFORE JULY 6, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT
What Is The Lawsuit About?
The complaint filed alleges that, between February 4, 2025 and February 2, 2026, Defendants failed to disclose to investors that: (1) Graphic Packaging was experiencing, inter alia, significant inventory management issues, as well as significantly reduced demand and volumes and increased costs; (2) Defendants downplayed the true scope and severity of the foregoing issues, which were likely to, and did, have a material negative impact on the Company's business and financial results; (3) Defendants likewise overstated the strength and sustainability of the Company's business model and operations, as well as its ability to weather ongoing macroeconomic headwinds; (4) accordingly, the Company's previously issued FY 2025 financial guidance was unreliable and/or unrealistic; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
